KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Cash & Current Investments (2018 - 2025)

Historic Cash & Current Investments for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $92.4 million.

  • Esperion Therapeutics' Cash & Current Investments fell 3611.88% to $92.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.4 million, marking a year-over-year decrease of 3611.88%. This contributed to the annual value of $144.8 million for FY2024, which is 7600.55% up from last year.
  • Esperion Therapeutics' Cash & Current Investments amounted to $92.4 million in Q3 2025, which was down 3611.88% from $86.1 million recorded in Q2 2025.
  • Esperion Therapeutics' Cash & Current Investments' 5-year high stood at $259.3 million during Q4 2021, with a 5-year trough of $82.2 million in Q4 2023.
  • In the last 5 years, Esperion Therapeutics' Cash & Current Investments had a median value of $162.3 million in 2023 and averaged $160.9 million.
  • Per our database at Business Quant, Esperion Therapeutics' Cash & Current Investments skyrocketed by 8263.47% in 2022 and then tumbled by 5453.82% in 2025.
  • Quarter analysis of 5 years shows Esperion Therapeutics' Cash & Current Investments stood at $259.3 million in 2021, then plummeted by 35.66% to $166.9 million in 2022, then crashed by 50.71% to $82.2 million in 2023, then surged by 76.01% to $144.8 million in 2024, then plummeted by 36.14% to $92.4 million in 2025.
  • Its Cash & Current Investments was $92.4 million in Q3 2025, compared to $86.1 million in Q2 2025 and $114.6 million in Q1 2025.